EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy

Yongqing Qin iD, Shisong Han iD, Yahan Yu, Ding Qi, Mengnan Ran, Mingqi Yang, Yanyan Liu, Yunyi Li, Ligong Lu, Yu Liu, Yong Li

Liver International · 2024-08 · 44 (8) · 1808-1831

DOI: 10.1111/liv.15953 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 03.05.2024. Verfasst von Yongqing Qin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Quinolines, Phenylurea Compounds, Liver Neoplasms. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 213 Literaturangaben. Gefördert von: Xiangshan Talented Scientific Research Foundation of Zhuhai People's Hospital, Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), one of the most prevalent and destructive causes of cancer‐related deaths worldwide, approximately 70% of patients with HCC exhibit advanced disease at diagnosis, limiting the potential for radical treatment. For such patients, lenvatinib, a long‐awaited alternative to sorafenib for first‐line targeted therapy, has become a key treatment. Unfortunately, despite some progress, the prognosis for advanced HCC remains poor because of drug resistance development. However, the molecular mechanisms underlying lenvatinib resistance and ways to relief drug resistance in HCC are largely unknown and lack of systematic summary; thus, this review not only aims to explore factors contributing to lenvatinib resistance in HCC, but more importantly, summary potential methods to conquer or mitigate the resistance. The results suggest that abnormal activation of pathways, drug transport, epigenetics, tumour microenvironment, cancer stem cells, regulated cell death, epithelial–mesenchymal transition, and other mechanisms are involved in the development of lenvatinib resistance in HCC and subsequent HCC progression. To improve the therapeutic outcomes of lenvatinib, inhibiting acquired resistance, combined therapies, and nano‐delivery carriers may be possible approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularQuinolinesPhenylurea CompoundsLiver NeoplasmsDrug Resistance, NeoplasmAntineoplastic AgentsHumansTumor MicroenvironmentEpithelial-Mesenchymal TransitionNeoplastic Stem CellsProtein Kinase Inhibitors

Stichwörter der Autor:innen

combination therapydrug resistancehepatocellular carcinomalenvatinib

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuhai, Gu…
  • School of Pharmacy, Guangdong Medical University, Zhanjiang, China.
  • Department of Nephrology, First Affiliated Hospital of Jinan University, Guangzhou, China.

ORCID-Profile: Yongqing Qin, Shisong Han

Förderung

  • Xiangshan Talented Scientific Research Foundation of Zhuhai People's Hospital
  • Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment
  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Zhuhai Industrial Core and Key Technology Tackling Direction Project

Zitieren

APA

Qin, Y., Han, S., Yu, Y., Qi, D., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., & Li, Y. (2024). Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. Liver International, 44(8), 1808-1831. https://doi.org/10.1111/liv.15953

Vancouver

Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M, et al. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. Liver International. 2024;44(8):1808-1831. doi:10.1111/liv.15953

BibTeX
@article{Qin2024,
  author = {Qin, Yongqing and Han, Shisong and Yu, Yahan and Qi, Ding and Ran, Mengnan and Yang, Mingqi and Liu, Yanyan and Li, Yunyi and Lu, Ligong and Liu, Yu and Li, Yong},
  title = {Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {8},
  pages = {1808--1831},
  doi = {10.1111/liv.15953}
}
Kostenlos starten →